{"nctId":"NCT02192814","briefTitle":"Open-label Study to Evaluate the Safety and Tolerability of iv Lacosamide in Japanese Adults With Partial-onset Seizures","startDateStruct":{"date":"2014-06"},"conditions":["Epilepsy","Partial-onset Seizures"],"count":9,"armGroups":[{"label":"Lacosamide (LCM)","type":"EXPERIMENTAL","interventionNames":["Drug: Lacosamide (200 mg/20 mL)"]}],"interventions":[{"name":"Lacosamide (200 mg/20 mL)","otherNames":["Vimpat"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Subject is Japanese and enrolled in EP0009 (NCT01832038) receiving oral Lacosamide (LCM) for the treatment of partial-onset seizures and has been enrolled for at least 8 weeks\n* Subject has been on a stable twice daily (bid) dosage regimen of LCM 200 mg/ day to 400 mg/ day, for the 2 weeks prior to entry into EP0024\n* Subject has been receiving no more than 3 concomitant Antiepileptic Drugs (AEDs) at doses that have remained stable for the 2 weeks prior to entry into EP0024\n\nExclusion Criteria:\n\n* Subject has a history of any kind of status epilepticus within 12-month period prior to study entry\n* Subject has actual suicidal ideation as indicated by a positive response (\"Yes\") to either Question 4 or Question 5 of the \"Since Last Visit\" version of the Columbia-Suicide Severity Rating Scale (C-SSRS)","healthyVolunteers":false,"sex":"ALL","minimumAge":"16 Years","stdAges":["CHILD","ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"The Total Number of Subjects Experiencing at Least One Adverse Event During the Study","description":"An Adverse Event (AE) is any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product that does not necessarily have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not related to the medicinal (investigational) product.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4","spread":null}]}]}]},{"type":"PRIMARY","title":"The Total Number of Subject Withdrawal Due to Adverse Events During the Study","description":"An Adverse Event (AE) is any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product that does not necessarily have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not related to the medicinal (investigational) product.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Plasma Trough Concentration (Ctrough) for Lacosamide (LCM) on Day 1","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.738","spread":"50.5"}]}]}]},{"type":"SECONDARY","title":"Plasma Trough Concentration (Ctrough) for Lacosamide (LCM) on Day 2","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.004","spread":"55.4"}]}]}]},{"type":"SECONDARY","title":"Plasma Trough Concentration (Ctrough) for Lacosamide (LCM) on Day 5","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.615","spread":"60.0"}]}]}]},{"type":"SECONDARY","title":"Maximum Plasma Concentration (Cmax) for Lacosamide (LCM) (End of Infusion) on Day 1","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"10.838","spread":"46.6"}]}]}]},{"type":"SECONDARY","title":"Maximum Plasma Concentration (Cmax) for Lacosamide (LCM) (End of Infusion) on Day 2","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"10.330","spread":"50.0"}]}]}]},{"type":"SECONDARY","title":"Maximum Plasma Concentration (Cmax) for Lacosamide (LCM) (End of Infusion) on Day 5","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"9.621","spread":"38.8"}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"The Cumulative Partial-onset Seizure Frequency From Day -1 to Day 5","description":"No descriptive statistics have been calculated for this exploratory Outcome Measure.","classes":[]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":9},"commonTop":["Abdominal pain upper","Toothache","Vomiting","Injection site erythema","Injection site pain"]}}}